Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 9/20 | 1.00 |
| ▸ | MMP2 | P08253 | 10/20 | 0.73 |
| ▸ | MMP9 | P14780 | 9/20 | 0.73 |
| ▸ | MMP3 | P08254 | 9/20 | 0.73 |
| ▸ | MMP13 | P45452 | 9/20 | 0.73 |
| ▸ | MMP1 | P03956 | 8/20 | 0.73 |
| ▸ | MMP7 | P09237 | 8/20 | 0.73 |
| ▸ | MMP8 | P22894 | 1/20 | 0.73 |
| ▸ | MMP14 | P50281 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7866140 | 0.88 | ADAMTS4 (0.81) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL8284708 | 0.86 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL1656895 | 0.86 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL1658525 | 0.86 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL8285408 | 0.86 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL7761520 | 0.84 | MMP2 (1.00) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL7761532 | 0.84 | MMP2 (1.00) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL8283964 | 0.84 | ADAMTS4 (0.84) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL8284079 | 0.83 | ADAMTS4 (0.82) | ADAMTS4MMP2MMP9MMP3MMP13 | |
| SCHEMBL1656285 | 0.83 | ADAMTS4 (0.71) | ADAMTS4MMP2MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923446-B2 | 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis | WYETH LLC (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923446-B2 | 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis | WYETH LLC (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923446-B2 | 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis | WYETH LLC (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1689380-A4 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-7390833-B2 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390833-B2 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390833-B2 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7268135-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268135-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268135-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1689380-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689716-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2005060456-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATE DISEASE | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061459-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061459-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP2 5/4885MMP9 14/4885 |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | ADAMTS5, ADAMTS1, ADAMTS4 | ADAMTS4 3/4885MMP2 119/4885MMP9 87/4885 |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | ADAMTS5, ADAMTS1, ADAMTS4 | ADAMTS4 3/4885MMP2 119/4885MMP9 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.